These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 21955398)
1. Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer. Wu Z; Doondeea JB; Gholami AM; Janning MC; Lemeer S; Kramer K; Eccles SA; Gollin SM; Grenman R; Walch A; Feller SM; Kuster B Mol Cell Proteomics; 2011 Dec; 10(12):M111.011635. PubMed ID: 21955398 [TBL] [Abstract][Full Text] [Related]
2. Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer. Wheeler SE; Morariu EM; Bednash JS; Otte CG; Seethala RR; Chiosea SI; Grandis JR Clin Cancer Res; 2012 May; 18(10):2850-60. PubMed ID: 22490227 [TBL] [Abstract][Full Text] [Related]
3. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323 [TBL] [Abstract][Full Text] [Related]
4. Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines. Hinz TK; Kleczko EK; Singleton KR; Calhoun J; Marek LA; Kim J; Tan AC; Heasley LE Mol Pharmacol; 2019 Dec; 96(6):862-870. PubMed ID: 31554698 [TBL] [Abstract][Full Text] [Related]
5. Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways. Raju U; Riesterer O; Wang ZQ; Molkentine DP; Molkentine JM; Johnson FM; Glisson B; Milas L; Ang KK Radiother Oncol; 2012 Nov; 105(2):241-9. PubMed ID: 23010482 [TBL] [Abstract][Full Text] [Related]
6. Functional kinomics identifies candidate therapeutic targets in head and neck cancer. Moser R; Xu C; Kao M; Annis J; Lerma LA; Schaupp CM; Gurley KE; Jang IS; Biktasova A; Yarbrough WG; Margolin AA; Grandori C; Kemp CJ; Méndez E Clin Cancer Res; 2014 Aug; 20(16):4274-88. PubMed ID: 25125259 [TBL] [Abstract][Full Text] [Related]
7. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192 [TBL] [Abstract][Full Text] [Related]
8. Kinome Profiling of Primary Endometrial Tumors Using Multiplexed Inhibitor Beads and Mass Spectrometry Identifies SRPK1 as Candidate Therapeutic Target. Kurimchak AM; Kumar V; Herrera-Montávez C; Johnson KJ; Srivastava N; Davarajan K; Peri S; Cai KQ; Mantia-Smaldone GM; Duncan JS Mol Cell Proteomics; 2020 Dec; 19(12):2068-2090. PubMed ID: 32994315 [TBL] [Abstract][Full Text] [Related]
9. Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells. Lin YC; Wu MH; Wei TT; Chuang SH; Chen KF; Cheng AL; Chen CC Neoplasia; 2012 Jun; 14(6):463-75. PubMed ID: 22787428 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of SRC family kinases reduces myeloid-derived suppressor cells in head and neck cancer. Mao L; Deng WW; Yu GT; Bu LL; Liu JF; Ma SR; Wu L; Kulkarni AB; Zhang WF; Sun ZJ Int J Cancer; 2017 Mar; 140(5):1173-1185. PubMed ID: 27798955 [TBL] [Abstract][Full Text] [Related]
11. Chemical Proteomics Uncovers EPHA2 as a Mechanism of Acquired Resistance to Small Molecule EGFR Kinase Inhibition. Koch H; Busto ME; Kramer K; Médard G; Kuster B J Proteome Res; 2015 Jun; 14(6):2617-25. PubMed ID: 25963923 [TBL] [Abstract][Full Text] [Related]
12. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Xu H; Stabile LP; Gubish CT; Gooding WE; Grandis JR; Siegfried JM Clin Cancer Res; 2011 Jul; 17(13):4425-38. PubMed ID: 21622718 [TBL] [Abstract][Full Text] [Related]
13. A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma. Radhakrishnan A; Nanjappa V; Raja R; Sathe G; Puttamallesh VN; Jain AP; Pinto SM; Balaji SA; Chavan S; Sahasrabuddhe NA; Mathur PP; Kumar MM; Prasad TS; Santosh V; Sukumar G; Califano JA; Rangarajan A; Sidransky D; Pandey A; Gowda H; Chatterjee A Sci Rep; 2016 Oct; 6():36132. PubMed ID: 27796319 [TBL] [Abstract][Full Text] [Related]
14. c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met. Stabile LP; He G; Lui VW; Thomas S; Henry C; Gubish CT; Joyce S; Quesnelle KM; Siegfried JM; Grandis JR Clin Cancer Res; 2013 Jan; 19(2):380-92. PubMed ID: 23213056 [TBL] [Abstract][Full Text] [Related]
15. Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells. Sutton P; Borgia JA; Bonomi P; Plate JM Mol Cancer; 2013 Jul; 12():76. PubMed ID: 23866081 [TBL] [Abstract][Full Text] [Related]
16. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. Han C; Michalopoulos GK; Wu T J Cell Physiol; 2006 Apr; 207(1):261-70. PubMed ID: 16331686 [TBL] [Abstract][Full Text] [Related]
17. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer. Li Z; Liao J; Yang Z; Choi EY; Lapidus RG; Liu X; Cullen KJ; Dan H Br J Cancer; 2019 Feb; 120(3):306-316. PubMed ID: 30585254 [TBL] [Abstract][Full Text] [Related]
18. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis. Lu H; Li X; Lu Y; Qiu S; Fan Z Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723 [TBL] [Abstract][Full Text] [Related]
19. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma. Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738 [TBL] [Abstract][Full Text] [Related]
20. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]